Panic disorder - Pipeline Insight, 2024

This “Panic disorder - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Panic disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Panic disorder Understanding

Panic disorder: Overview

Panic disorder is an anxiety disorder where you regularly have sudden attacks of panic or fear. People with Panic disorder have sudden and repeated attacks of fear that last for several minutes or longer. These are called panic attacks. Panic attacks are characterized by a fear of disaster or of losing control even when there is no real danger. A person may also have a strong physical reaction during a panic attack. It may feel like having a heart attack. Panic attacks can occur at any time, and many people with Panic disorder worry about and dread the possibility of having another attack. A person with Panic disorder may become discouraged and feel ashamed because he or she cannot carry out normal routines like going to school or work, going to the grocery store, or driving. Panic disorder often begins in the late teens or early adulthood. More women than men have Panic disorder. But not everyone who experiences panic attacks will develop Panic disorder.

Panic disorder - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Panic disorder pipeline landscape is provided which includes the disease overview and Panic disorder treatment guidelines. The assessment part of the report embraces, in depth Panic disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Panic disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Panic disorder R&D. The therapies under development are focused on novel approaches to treat/improve Panic disorder.

Panic disorder Emerging Drugs Chapters

This segment of the Panic disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Panic disorder Emerging Drugs

Darigabat: Cerevel TherapeuticsDarigabat was rationally designed as an orally-bioavailable, twice-daily positive allosteric modulator (PAM) that selectively targets GABAA receptors containing alpha-2/3/5 subunits. Darigabat is designed as a PAM to increase the effect of endogenous GABA without blocking or overexciting normal neural activity and with a lower propensity for development of tolerance. Currently, it is in Phase I stage of clinical trialevaluation to treat Panic disorder.

Panic disorder: Therapeutic Assessment

This segment of the report provides insights about the different Panic disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Panic disorder

There are approx. 4+ key companies which are developing the therapies for Panic disorder. The companies which have their Panic disorder drug candidates in the most advanced stage, i.e. phase I include, Cerevel Therapeutics.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Panic disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Panic disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Panic disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Panic disorder drugs.

Panic disorder Report Insights

• Panic disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Panic disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Panic disorder drugs?
• How many Panic disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Panic disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Panic disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Panic disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cerevel Therapeutics
• Janssen Research & Development
• Addex Pharmaceuticals
• Neurelis
• VistaGen Therapeutics

Key Products

• Darigabat
• JNJ 61393215
• ADX 71149
• NRL-2
• PH94B

This product will be delivered within 1-3 business days.